Humanin

What Humanin does

Humanin is a peptide the body makes, studied for cell protection. Injection benefits and safety remain unproven. People use it hoping for longevity, better sleep or brain protection. Human studies measure natural levels. Dosing and cancer effects remain unresolved.

• In animal studies, it lengthened lifespan in worms and improved some health measures in mice; this has not been tested in people. (animal)
• In lab studies, humanin protected nerve cells from several kinds of damage linked to Alzheimer's disease. (animal)
• A few people report longer, unbroken sleep, but no human trial has tested humanin for sleep. (Reported by users)

Uses in the sources

• Users seek longevity benefits. Lifespan findings come from worms and other laboratory models, not human treatment trials. (Reported by users) (source)
• A few users report better sleep. No human trial has tested humanin for sleep. (Reported by users) (source)
• Users discuss brain protection; cell and mouse findings do not establish improved cognition in people taking humanin. (Reported by users) (source)

Humanin dosage

Typical reported dose: 500 mcg once a day

• 500 mcg daily report: 500 mcg daily daily, under the skin. Reported by users, rare report. Studied in: Adults reporting self-use online; age and product identity are not independently verified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Humanin

Comes as: Powder vial and mixed injection solution, community-reported.

Mixed with: Bacteriostatic water is discussed online; no approved diluent or reconstitution method is established..

• No reliable common vial size or water-volume standard was identified from non-selling sources.
• Opening powder vials to weigh and split contents risks loss of sterility; a purity result cannot establish sterility.
• Claims that humanin lasts only hours after mixing were not supported by validated stability studies.

Before mixing: No validated patient-use storage specification was found.

After mixing: No validated shelf life after mixing was found; community discussions explicitly disagree.

Humanin side effects and risks

Reported side effects

• Injection-related allergy or infection: General unapproved injectable risk; no humanin specific event rate., serious. Breathing difficulty needs emergency care; spreading painful redness needs urgent review. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse: Stop exposure and call emergency services now. Use prescribed adrenaline if available.
• Spreading hot, painful injection-site redness, especially with fever: Stop injections and seek same-day care; confusion or fainting needs emergency care.
• Confusion, seizure, collapse or low blood sugar that does not resolve: Call emergency services for severe symptoms; follow the established diabetes rescue plan if applicable.

Who should avoid it

• pregnant: Precaution: no administered-peptide pregnancy safety data were identified.
• breastfeeding: Precaution: transfer into milk and effects on a nursing infant are unknown.
• tryingToConceive: Precaution: human fertility and embryo safety after injected peptide are unknown.
• under18: Precaution: no pediatric dosing or injection-safety data were identified.
• diabetes: Glucose effects and interactions with diabetes medicines are untested in humans.
• kidneyDisease: Human clearance and dose adjustment in kidney disease have not been established.
• liverDisease: Human exposure and dose adjustment in liver disease have not been established.
• heartCondition: Cardiac biomarker studies do not establish injection safety in people with heart disease.
• surgeryPlanned: Tell the care team about use; perioperative drug interactions and safety are unknown.
• activeCancer: Precaution: humanin promoted glioblastoma growth and blood-vessel formation in mice; it also blocks cell-death pathways.
• cancerHistory: Discuss recurrence risk; cell-survival signaling and a tumor-growth signal make long-term cancer safety uncertain.
• testedAthlete: Prohibited at all times under WADA 2026 S0 for non-approved pharmacological substances.

Interactions

• Insulin and sulfonylureas: Possible added glucose lowering is theoretical. No human interaction study has measured the risk.
• Metformin and other glucose-lowering medicines: Combination effects on glucose, appetite and exercise tolerance are untested for injected humanin.
• Anticoagulants and antiplatelets: No compound-specific interaction is established. Review injection-related bleeding risk with the prescriber.
• Other mitochondrial peptides: No human trial establishes the safety or benefit of stacking mitochondrial peptides. HNG is not native humanin.
• Cancer treatment: Precaution: cell-survival signaling may affect cancer biology; a glioblastoma model showed tumor promotion. Human combination safety is unknown.
• Growth hormone and IGF-1 therapies: GH/IGF-1 can alter endogenous humanin. The safety of adding humanin injections has not been tested.

Product quality risks

• Unapproved injectable products can have too much, too little or none of the stated ingredient.
• Possible contaminants include microbes, endotoxins, solvents, metals and particles; risk varies by batch.
• No independent market-wide test of native MOTS-c or humanin products was identified.

What to expect

No verified direct-administration human studies in the reviewed record. Human biomarker studies and experiments administering humanin to animals are separate evidence.

Key studies

• Severe Klebsiella infection: Serum humanin was higher during infection, p<0.001. Treatment experiments were in mice, not patients. (source)
• Heart-failure rehabilitation: At 6 months, cardiac events occurred in 24/71 vs 41/83, p=0.051. The humanin/CRP ratio was an observational risk marker. (source)
• Water exercise in older women: The study measured humanin after 12 weeks of training; its abstract reports no separate humanin effect estimate. (source)
• Hemodialysis risk models: 33 had a cardiovascular event; both low <462 and high >778 pg/mL humanin were linked to increased risk. (source)
• Exercise and astaxanthin: Humanin rose after combined exercise with or without astaxanthin, p<0.05. No humanin injections were used. (source)
• PCOS serum and muscle: Median humanin was 474.9 vs 672.3 pg/mL, p<0.001; muscle levels did not differ, p=0.71. (source)

Humanin FAQ

• Is Humanin FDA-approved? No FDA label or approved product was identified. A UNII identifies a substance and does not mean FDA approval.
• How do people take it? Under the skin, daily. 11 days of daily use reported; later exposure was an accidental dosing error.. Source: reported by users, not an established dose.
• What's the difference between Humanin and MOTS-c? Humanin: a peptide the body makes; injection benefits and safety remain unproven. MOTS-c: a peptide the body makes; injection benefits and safety remain unproven. Why people pair them: users combine mitochondrial peptides for energy, sleep or longevity goals.
• Can I take it with MOTS-c? Users combine mitochondrial peptides for energy, sleep or longevity goals. No human trial has tested this combination; safety and added benefit are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Applies the non-approved pharmacological-substance rule; humanin is not individually named.
• How long does a mixed vial last? No validated shelf life after mixing was found; community discussions explicitly disagree.